In addition to LAG-3 antagonists, the use of IMP321 in combination with pembrolizumab, an anti-PD-1, is also under investigation in advanced melanoma (NCT02676869).85 IMP321, also known as Eftilagimod alpha, is a soluble version of anti-LAG-3. Here, PDCD1 is linked to melanoma.